New York is currently home to 4467 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Cardiopulmonary Exercise Testing and Oscillometry for the Evaluation of Dyspnea
Recruiting
This study will determine if airway resistance to airflow and pressure, measured by Oscillometry, is associated with abnormal findings on Cardiopulmonary Exercise Testing in subjects who are experiencing shortness of breath.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Highland Hospital, Rochester, New York
Conditions: Breathing, Mouth, Lung Function Decreased, Dyspnea, Shortness of Breath
TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.
Recruiting
This will be a double-blind randomized control trial in women with stress urinary incontinence who are undergoing an outpatient transurethral bulking procedure for stress urinary incontinence. Subjects will be identified by the University of Rochester urologists and urogynecologists participating in the study who currently oversee stress incontinence care. Subjects will be randomized into two groups. One group will be undergoing the cystoscopy with transcutaneous electrical nerve stimulation (TE... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Pelvic Health and Continence Specialties, Rochester, New York
Conditions: Stress Incontinence Female, Urinary Incontinence, Urinary Incontinence,Stress, Pain, Pain Acute
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Recruiting
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the liver (liver metastases) and cannot be removed by surgery (unresectable). HAI uses a catheter to carry a tumor-killing chemotherapy drug called floxuridine directly into the liver. HAI is already approved by the Food and Drug Administration (FDA) for use in metas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Memorial Sloan Kettering Commack, Commack, New York
Conditions: Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Recruiting
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Columbia University Medical Center, New York, New York
Conditions: Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
Recruiting
This is a pilot, single-center, single-arm study where 20 patients with metastatic or unresectable clear cell renal cell carcinoma will receive same sequential treatment strategy (Cabozantinib for 12 weeks, then proceed with Ipilimumab plus Nivolumab immunotherapy x4 over 12 weeks, then subsequent therapies depending on treatment response for another 12 weeks \[Nivolumab for CR/PR/SD, Cabozantinib or Lenvatinib/Everolimus for PROG\]).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/04/2024
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Renal Cell Carcinoma
Biologics and Clinical Immunology Cohort At Sinai
Recruiting
The study team plans to establish a bioregistry of patients receiving biologic therapy as part of their standard treatment at the Mount Sinai Therapeutic Infusion Center and affiliated practices. The study team will to apply state-of-the-art approaches to assessing and predicting immunological and clinical responses associated with these standards and prescribed treatments. The approach is twofold. The first component is to establish a robust and flexible biorepository and database that includes... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
11/04/2024
Locations: Mount Sinai, New York, New York
Conditions: Immunological Disease, Autoimmune Diseases, Primary Immune Deficiency
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Recruiting
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the pr... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Northwell Health Imbert Cancer Center, Bay Shore, New York
Conditions: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Post-Traumatic Stress Disorder Focused Psychodynamic Psychotherapy
Recruiting
This is a randomized controlled trial of Trauma-Focused Psychodynamic Psychotherapy (TFPP) in comparison with TAU (at the VA) in a 2:1 ratio in 75 Veterans with PTSD who have not responded to standard treatment at the VA.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
11/04/2024
Locations: VA New York Harbor Healthcare System - Manhattan Campus, New York, New York
Conditions: PTSD
A Safety and Effectiveness Prospective Blinded Clinical Study to Validate xBar System as Monitoring Tool for Anastomotic Leaks Detection
Recruiting
Purpose: To validate the safety and effectiveness of xBar monitoring tool for detection of post-operative anastomotic leaks in subjects undergoing rectal/sigmoid resections with anastomosis. The clinical team is blinded to the leak detection of the xBar system.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
11/03/2024
Locations: Weill Cornell MC, NY, New York, New York
Conditions: Colorectal Surgery, Anastomotic Leak
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
Recruiting
In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled. The study is open-label, randomized with active control, multi-center study.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: Roswell Park Comprehensive Cancer Center - 1625, Buffalo, New York
Conditions: Metastatic Castration-resistant Prostate Cancer
Single Position Spine Surgery Registry
Recruiting
The purpose of this study is to systematically, prospectively compare surgical fusion techniques for thoracolumbar spinal fusion patients and assess long-term patient outcomes and revision rates following surgery.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
11/01/2024
Locations: NYU Langone Health, New York, New York
Conditions: Spine Fusion, Spinal Stenosis, Degenerative Disc Disease
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients with DLBCL
Recruiting
The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.
Gender:
ALL
Ages:
75 years and above
Trial Updated:
11/01/2024
Locations: University of Rochester, Rochester, New York
Conditions: DLBCL, Lymphoma, B-Cell